Neogen (NEOG)
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-30
$11.82-3.59%
Close 2026-10-30 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-30
Research Workspace
Put NEOG beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Supplies is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is contracting — down about 0% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 28% in its worst 12-month stretch.
View RiskNEOG’s Food Safety growth must sustain its recovery to support its premium valuation. Revenue growth improved from slightly negative in fiscal Q4 to 6.5% in Q1 FY2027. Q1 adjusted earnings beat consensus, and management raised fiscal 2027 revenue guidance. NEOG trades at 35× P/E versus the 22× peer median. The market prices more growth than our forecast, leaving that premium to be earned. Our model puts the next-quarter miss probability near 26%. Peer multiples imply a price about 50% below where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. NEOG is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering NEOG (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare NEOG with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NEOG Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Supplies — fair value, gap to price, and forward P/E.
Compare the value case
Put NEOG next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive growth in Food Safety segment
Increased R&D supports growth in Food Safety segment.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase FY27 revenue guidance to $880-$890 million
Increases revenue guidance aligns with growth objectives.
Advances: Increase FY26 revenue guidance to $857-$860 million
Earnings beat indicates strong operational performance.
Advances: Increase FY26 revenue guidance to $857-$860 million
Stock increase reflects positive market reaction to guidance.
Pending investigation could affect investor confidence and operations.
Advances: Divest global Genomics business by 2Q27
Divesting Genomics aligns with capital allocation objectives.
Advances: Increase FY26 revenue guidance to $857-$860M
Earnings beat supports revenue growth guidance for FY26.
Profit surge supports revenue growth objectives.
